Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 6/20 | 0.44 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29777648 | 0.97 | ACE (0.49) | ACECTRB1F2NTMT1PRCP | |
| SCHEMBL29566581 | 0.94 | CTRB1 (0.46) | ACECTRB1F2PRCPFDFT1 | |
| SCHEMBL29777638 | 0.91 | ACE (0.47) | ACEF2NTMT1PRCPTLR2 | |
| SCHEMBL30585183 | 0.89 | CTRB1 (0.45) | CTRB1F2PRCPFDFT1TLR2 | |
| SCHEMBL29858987 | 0.89 | CTRB1 (0.46) | CTRB1F2PRCPFDFT1TLR2 | |
| SCHEMBL29777748 | 0.88 | ACE (0.45) | ACEF2NTMT1PRCPTLR2 | |
| SCHEMBL29777548 | 0.88 | TLR2 (0.44) | CTRB1F2NTMT1PRCPTLR2 | |
| SCHEMBL29561678 | 0.88 | CTRB1 (0.42) | CTRB1F2PRCPFDFT1MDM2 | |
| SCHEMBL29749447 | 0.88 | CTRB1 (0.48) | CTRB1F2FDFT1 | |
| SCHEMBL29706288 | 0.87 | CTRB1 (0.55) | CTRB1F2FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116333053-A | Atosiban and method for inhibiting formation of polymeric impurities | 海南中和药业股份有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-111393508-B | Preparation method of atosiban | 上海苏豪逸明制药有限公司 | 2023-05-12 | — | — | CN | claimed |
| CN-115038711-B | Synthesis method of atosiban | 湖北健翔生物制药有限公司 | 2023-05-02 | — | — | CN | claimed |
| CN-115038711-A | Synthetic method of atosiban | 湖北健翔生物制药有限公司 | 2022-09-09 | — | — | CN | claimed |
| WO-2022141615-A1 | SYNTHESIS METHOD FOR ATOSIBAN | 湖北健翔生物制药有限公司 | 2022-07-07 | — | — | WO | claimed |
| CN-114685614-B | Solid-phase synthesis method of atosiban | 湖北健翔生物制药有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-116333053-A | Atosiban and method for inhibiting formation of polymeric impurities | 海南中和药业股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-111393508-B | Preparation method of atosiban | 上海苏豪逸明制药有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-115038711-B | Synthesis method of atosiban | 湖北健翔生物制药有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115038711-B | Synthesis method of atosiban | 湖北健翔生物制药有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115461355-A | Method for preparing atosiban | 厦门胜泽泰医药科技有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-115038711-A | Synthetic method of atosiban | 湖北健翔生物制药有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115038711-A | Synthetic method of atosiban | 湖北健翔生物制药有限公司 | 2022-09-09 | — | — | CN | disclosed |
| WO-2022141615-A1 | SYNTHESIS METHOD FOR ATOSIBAN | 湖北健翔生物制药有限公司 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022141615-A1 | SYNTHESIS METHOD FOR ATOSIBAN | 湖北健翔生物制药有限公司 | 2022-07-07 | — | — | WO | disclosed |
| CN-114685614-A | Solid-phase synthesis method of atosiban | 湖北健翔生物制药有限公司 | 2022-07-01 | — | — | CN | disclosed |